Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl

NCT ID: NCT01062191

Last Updated: 2011-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the difference in joint range of motion of a new flexible hydrogel nanoparticle wound dressing compared to typical sodium carboxymethylcellulose dressing Aquacel AG for treatment of partial thickness burns.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single center, randomized, single blind therapeutic exploratory study to monitor the range of motion of wounds treated with the new nanoparticle hydrogel dressing compared to the range of motion of wounds treated with existing treatment standard (sodium carboxymethylcellulose dressing) in patients with partial thickness burns. A total of 50 joints will be studied. The patients will be at least 7 years of age.. The Department of Physical Medicine and Rehabilitation at Parkland Hospital and Health System, UT Southwestern, will be asked to enroll enough patients to meet the proposed 50 joint study sites (approximately 3-5 afflicted joints per patient). Children will be included in the patient population if possible. Inclusion criteria for the medical condition will be at least one partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints. As a control, the patients will also need to have an unburned contralateral joint without major internal or external joint derangement.

The Primary Investigator will first identify the study site and control site for each patient and take the initial measurements. Trained personnel will apply the bandage to the study site. No secondary bandage will be applied. Typical meticulous wound care and adequate analgesic medical coverage will be provided for the duration of the study. Both the patient and medical staff will be trained on patient use instructions for the dressing. The patients will be monitored for a short time after application of the bandage as part of standard procedure, and the patient is then allowed to go home with instructions for care. Within 2-8 days after application, the dressing will be inspected and range of motion will be measured for both the study site and the control site. Any concomitant treatment (medications, wound care) will be thoroughly documented for the duration of the study. Both dressings are designed to remain on the wound until the bandage falls off, which indicates re-epithelialization of the wound. The dressings should not be removed by the patient or medical staff unless there are signs of infection, deterioration of bandage, or other adverse event. If the bandage falls off, the patient is instructed to immediately call the medical staff.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing

Nanoflex Powder Dressing applied to joint

Group Type EXPERIMENTAL

Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing

Intervention Type DEVICE

Wound dressing

Aquacel AG, typical carboxymethylcellulose dressing

Sodium CMC dressing control applied to joint

Group Type ACTIVE_COMPARATOR

Aquacel AG, typical carboxymethylcellulose dressing

Intervention Type DEVICE

4" X 4", Aquacel silver sheet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aquacel AG, typical carboxymethylcellulose dressing

4" X 4", Aquacel silver sheet

Intervention Type DEVICE

Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing

Wound dressing

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patient is at least 2 years of age;
2. Patient is in general good health;
3. Patient has partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints;
4. Patient has one unburned contralateral joint without major internal or external joint derangement to be used as control
5. Patient is willing and able to cooperate with the protocol for 30 days
6. Patient is capable of provided informed consent
7. Patient provides authorization for use and disclosure of protected health information

Exclusion Criteria

1. Age less than 2 years;
2. Patient has superficial or full thickness burn wounds;
3. Patient has acutely infected wounds;
4. Patient has wounds with surrounding cellulites;
5. Patient has a history of hypersensitivity to any components of either the nanoparticle or sodium hydrocellulose dressing, or any know sensitivities to other hydrogel bandage treatments
6. Patient has a concurrent clinical condition, which in the judgment of the Investigator cold either pose a health risk to the patient while participating in this study, or could potentially influence the outcome of the study;
7. Patient is wearing any type of orthopedic device that may come in contact with the dressing;
8. Patient has history of poor wound healing, history of smoking, history of drug/alcohol abuse, any other skin/immune system condition that would increase likelihood of wound irritation, infection or increase chance of early termination
9. Patient has wound originating from chronic condition
10. Patients with history of any immunodeficiency syndrome or condition
11. Patients who have applied any dressing or medication (OTC or prescription) to the wound (within 48 hours of study? )
12. Patient has participated in a clinical research study within the last 30 days prior to enrollment;
13. Patient is unable to communicate or to cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ULURU Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

UTSW Medical Center, Department of Physical Medicine and Rehabilitation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UT Southwestern

Dallas, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U-C-6U1101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.